Despite this heterogeneity, it has been possible to sub-type prostate cancers based not only on gene fusion status but also on the abundance of mutations associated with biological drivers of the disease, and in particular mutations affecting androgen receptor (AR) signalling), PI 3-Kinase/Akt, and DNA repair pathways (3). This evidence concerns the gene AR and prostate cancer.